Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure
Free accessOtherFirst published online March, 2008
Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure
Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of β1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol. Thirty-seven subjects treated with carvedilol (32.9 ± 3.5 mg; n = 23) or metoprolol succinate (XL) (96.4 ± 15.9 mg; n = 14) referred for cardiopulmonary exercise testing were studied prospectively. Carvedilol versus metoprolol XL subjects did not differ with respect to baseline heart rate (73 ± 2 vs 70 ± 3 bpm), or baseline plasma norepinephrine levels (597.5 ± 78.3 vs 602.1 ± 69.6 pg/mL), P = NS. However, despite similar peak exercise norepinephrine levels (2735.8 ± 320.1 vs 2403.1 ± 371.6 pg/mL), heart rate at peak exercise was higher in subjects receiving carvedilol (135 ± 4 bpm) than those receiving metoprolol XL (117 ± 6 bpm), P = 0.02. Similar norepinephrine release and more complete β1-blockade is observed in well-matched subjects with chronic heart failure treated with a mean daily dose of metoprolol XL 96.4 mg compared with carvedilol 32.9 mg.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
2.
Packer M., Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NHThe effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
3.
Packer M., Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med.2001;344:1651-1658.
4.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) . Lancet. 1999; 353:2001-2007.
5.
Frishman W.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J.1979;97:663-670.
6.
Frishman W., Silverman R.Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects. Am Heart J. 1979;97:797-807.
7.
Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther.1992;263:92-98.
8.
Poole-Wilson PA, Swedberg K., Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
9.
Bristow MRWhat type of beta-blocker should be used to treat chronic heart failure? Circulation. 2000;102:484-486.
10.
Naughton J. , Sevelius G., Balke B.Physiological responses of normal and pathological subjects to a modified work capacity test. J Sports Med Phys Fitness. 1963;44: 201-207.
11.
De Mey C., Breithaupt-Grogler K., Schloos J., Palm D., Belz GGReproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol . 1994;38:480-483.
12.
Kjaer A., Appel J., Hildebrandt P., Petersen CLBasal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects. Eur J Heart Fail. 2004;6:29-39.
13.
van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition . Int J Cardiol.2006; 106:367-372.
14.
Boerrigter G., Burnett JCEndothelin in neurohormonal activation in heart failure. Coron Artery Dis. 2003;14: 495-500.
15.
Nicholls DP , Onuoha GN, McDowell G., et al. Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol. 1996;91 (Suppl 1):13-20.
16.
Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JNActivity of the sympathetic nervous system and reninangiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982 ;49:1659-1666.
17.
Lang CC, Rayos GH, Chomsky DB, Wood AJ, Wilson JREffect of sympathoinhibition on exercise performance in patients with heart failure. Circulation. 1997; 96:238-245.
18.
Drexler H.Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors. Eur Heart J.1991;12 (Suppl C):21-28.
19.
Grundemar L. , Hakanson R.Multiple neuropeptide Y receptors are involved in cardiovascular regulation. Peripheral and central mechanisms. Gen Pharmacol. 1993;24:785-796.
20.
Ennezat PV, Malendowicz SL, Testa M., et al. Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes. J Am Coll Cardiol.2001;38:194-198.
21.
Sullivan MJ, Higginbotham MB, Cobb FRExercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation. 1988;78:506-515.
22.
Varin R., Mulder P., Richard V., et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation. 1999;99: 2951-2957.
23.
Belardinelli R., Georgiou D., Scocco V., Barstow TJ, Purcaro A.Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol. 1995; 26:975-982.
24.
Hambrecht R., Niebauer J., Fiehn E., et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol. 1995;25:1239-1249.
25.
Herman RB, Jesudason PJ, Mustafa AM, Husain R., Choy AM, Lang CCDifferential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol. 2003 ;55:134-138.
26.
Azevedo ER, Kubo T., Mak S., et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity . Circulation. 2001;104:2194-2199.
27.
Newton GE, Parker JDAcute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation. 1996;94:353-358.
28.
Stoschitzky K., Koshucharova G., Zweiker R., et al. Differing beta-blocking effects of carvedilol and metoprolol. Eur J Heart Fail. 2001;3:343-349.
29.
Billeh R., Hirsh D., Barker C., et al. Randomized, Double-Blind Comparison of Acute beta1-Blockade With 50 mg Metoprolol Tartrate vs 25 mg Carvedilol in Normal Subjects. Congest Heart Fail. 2006;12:254-257.
30.
Sanderson JE , Leung LY, Chan SK, Yip GW, Fung JW, Yu CMDo metoprolol and carvedilol have equivalent effects on diurnal heart rate in patients with chronic heart failure? Eur J Heart Fail. 2005;7:874-877.
31.
Gilbert EM, Abraham WT, Olsen S., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-2825.
Murthy SS, Shetty HU, Nelson WL, Jackson PR, Lennard MSEnantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochem Pharmacol. 1990;40:1637-1644.
34.
Sachse C., Brockmoller J., Bauer S., Roots I.Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
35.
Zineh I., Beitelshees AL, Gaedigk A., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther.2004;76:536-544.
36.
Ismail R., Teh LKThe relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther. 2006;31:99-109.
37.
Johnson JA, Burlew BSMetoprolol metabolism via cytochrome P4502D6 in ethnic populations. Drug Metab Dispos. 1996;24:350-355.
38.
Lennard MS, Tucker GT, Silas JH, Freestone S., Ramsay LE, Woods HFDifferential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther. 1983;34:732-737.
39.
Silas JH, Lennard MS, Tucker GT, Ramsay LE, Woods HFPolymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol.1984;17 (Suppl 1):11S-19S.
40.
Fux R., Morike K., Prohmer AM, et al. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther. 2005;78:378-387.
41.
Liggett SBPharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology. 2000;61:167-173.
42.
Moore JD, Mason DA, Green SA, Hsu J., Liggett SBRacial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat . 1999;14:271.
43.
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med.2001;344:1659-1667.
44.
Shekelle P. , Morton S., Atkinson S., et al. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Evid Rep Technol Assess (Summ). 2003;82:1-6.
45.
Neugebauer G., Akpan W., von Mollendorff E., Neubert P., Reiff K.Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol.1987;10 (Suppl 11):S85-S88.
46.
Bristow MR, Feldman AM, Adams KF, Jr, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?J Card Fail. 2003;9:444-453.
47.
Kindermann M., Maack C., Schaller S., et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo . Circulation. 2004;109:3182-3190.
48.
Talbert RLPharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev. 2004; 9:131-137.
49.
Sandberg A. , Blomqvist I., Jonsson UE, Lundborg P.Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol.1988;33 (Suppl): S9-S14.
